Table 2.
FDA approved drugs that caused significant disruption in the barrier function of the bEnd3 cells-based BBB model from the primary screen.
| Drug | Descriptiona |
|---|---|
| Bexarotene | Highly selective retinoid X receptor (RXR) agonist |
| Colchicine | Prevents tubulin polymerization |
| Demeclocycline | Tetracycline antibiotic; interferes with protein synthesis |
| Felodipine | L-type calcium channel blocker |
| Idarubicin | Antineoplastic |
| Oxybutynin | Muscarinic acetylcholine receptor antagonist |
| Reserpine | Inhibits vesicular catecholine and serotonin uptake. |
| Topotecan | Topoisomerase I (topo-I) inhibitor |
| Vincristine | Inhibitor of microtubule assembly |
| Vinblastine | Inhibitor of microtubule assembly |
a
Sigma Aldrich Website, http://www.sigmaaldrich.com/chemistry/drug-discovery/validation-libraries/lopac1280-navigator.html.